These data also indicates that UHRF1 might be a potential therapeutic target in which the downregulation/inhibition would help to decrease some of the biological processes involved in the metastatic progression as it was shown recently for esophageal squamous cell carcinoma [70] or increased sensitivity of chemotherapeutic target as shown in breast cancer [71]. Here, UHRF1 is linked to breast cancer.